Bionyra Pharma

Bionyra Pharma is a private clinical-stage biopharmaceutical company focused on next-generation biologics for severe immune-mediated inflammatory diseases. Launched publicly in June 2026, the Paris- and Boston-based company is advancing a pipeline of mono- and multispecific antibodies engineered with half-life extension technology to improve durability and convenience. Its disclosed programs include BYN-002, an anti-TL1A monoclonal antibody in Phase 1; BYN-003, a TL1A x IL-23p19 bispecific antibody in Phase 1; and BYN-001, an anti-IL-25 monoclonal antibody at the IND/preclinical stage for atopic dermatitis and related type 2 inflammatory conditions. Bionyra was co-founded by Sofinnova Partners and Frédéric Marrache and launched with a $165 million oversubscribed Series A financing led by Jeito Capital and Sofinnova Partners. The company's strategy centers on selectively modulating novel immune pathways to deliver deeper and more durable disease control in indications such as inflammatory bowel disease and atopic dermatitis.